A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7252 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2018
At a glance
- Drugs MK-7252 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 11 Apr 2018 Planned End Date changed from 10 Apr 2018 to 23 Apr 2018.
- 11 Apr 2018 Planned primary completion date changed from 10 Apr 2018 to 23 Apr 2018.
- 05 Mar 2018 The treatment table has been amended to reduce the dosage of MK-725. Patients now receive all the treatment in Fasted state. No fed state.